Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients

NCT03221842 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT03221842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03221842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Terminated
Start date
November 6, 2017
Completion date
January 20, 2021
Enrollment
63 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection